Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 132   

Articles published

NVS 86.17 -0.39 (-0.45%)
price chart
Bullish Stocks: Allergan (NYSE:AGN), Comcast Corporation (NASDAQ:CMCSA ...
Swiss pharmaceutical firm Novartis AG (ADR) (NYSE:NVS) launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.
Buzz Stocks: Tesla Motors Inc (TSLA), Novartis AG (ADR), Allergan, Inc., and ...  Schaeffers Research (blog)
Related articles »  
Novartis Trying to Simplify Business; Announces Deals With Glaxo And Eli Lilly
Novartis AG (ADR) (NVS) announced plans to overhaul its business today. The company plans to sell two units and buy another, in multiple transactions totaling $25 billion, which have the potential to increase to as much as $28.5 billion.
ADR Shares End Mixed; Novartis, Glaxo, Philips Shares Active  Wall Street Journal
GlaxoSmithKline plc (ADR) (NYSE:GSK) Divests Cancer Unit, Enters Joint ...  US Trade Media
Related articles »  
Almirall Quietly Building A Better Business
With that delay, Novartis (NVS) may well make it to market ahead of Forest/Almirall with the second LAMA+LABA combo. This isn't a trivial issue, as peak sales for the drug (single and combo) could top out between $1.75 billion and $2 billion against ...
Related articles »  
Hot Stocks: Allergan, Inc. (NYSE:AGN), Novartis AG (ADR) (NYSE:NVS), Netflix ...
Shares of Allergan, Inc. (NYSE:AGN) are surging as Valeant Pharmaceuticals International Inc. offered to buy Allergan for about $152.89 a share in a cash-and-stock deal that will give Valeant the Botox wrinkle treatment, according to Bloomberg ...
Valeant, Ackman joins forces to nab Allergan  bnn.ca (blog)
Valeant Pharmaceuticals May Be Allergan's Best Offer: Analysts  ValueWalk
Related articles »  
Novartis Gets Breakthrough Status For Oncology Drug
Novartis AG (ADR) (NVS) announced on March 26 that the US Food and Drug Administration (FDA) has granted its investigational compound, certinib (LDK378), a ´┐Żbreakthrough therapy´┐Ż status.
Related articles »  
Biotech Stocks With Exciting Development Projects
biotechnology Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios.
Related articles »  
Novartis' Lead Ceritinib Could Capture Market Share From Pfizer
Novartis A.G. and worldwide collaborators published results of their Phase I clinical trial of the ALK inhibitor Ceritinib (LDK378) in the New England Journal of Medicine on March 27.
Related articles »  
Stocks Hot In News: Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE
Swiss pharmaceutical giant Novartis AG (ADR) (NYSE:NVS) announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its ...
Novartis reshuffles Japanese management following scandals
The reshuffle comes after Novartis said yesterday that staff hid severe side effects that some patients suffered in a trial for a leukemia drug.
Related articles »  
Traders Recap - Seattle Genetics, Inc (NASDAQ:SGEN), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.
Related articles »